SLC6A3 and Parkinson disease: Ultimately, PD patients requiring DAT are likely to have altered GM compositions prior to DAT initiation due to multiple factors, including older age, longer disease duration, motor fluctuation, increased GI dysfunction (namely constipation) and are likely to require more PD medication classes and increased dosages, when compared to those who don’t require DAT.